Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma Post date 10 February 2026 ← Ethnic inequality in prostate cancer: no current role for screening but hope for the future → Cancer and waiting lists: Recruitment bans and cancelled operations are derailing progress, leaders warn